| IART Stock | | | USD 24.72 2.67 12.11% |
CEO
Jan Witte is CEO President of Integra LifeSciences Holdings
| Age | 61 |
| Phone | 609 275 0500 |
| Web | https://www.integralife.com |
Integra LifeSciences Management Efficiency
The company has return on total asset
(ROA) of
0.0311 % which means that it generated a profit of $0.0311 on every $100 spent on assets. This is way below average. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities.
Integra LifeSciences Holdings currently holds 1.68
B in liabilities with Debt to Equity
(D/E) ratio of 1.03, which is about average as compared to similar companies. Integra LifeSciences has a current ratio of 3.77, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Integra LifeSciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Integra Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 3800 people. Integra LifeSciences Holdings (IART) is traded on NASDAQ Exchange in USA. It is located in 1100 Campus Road, Princeton, NJ, United States, 08540 and employs 3,946 people. Integra LifeSciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification.
Management Performance
Integra LifeSciences Leadership Team
Elected by the shareholders, the Integra LifeSciences' board of directors comprises two types of representatives: Integra LifeSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integra. The board's role is to monitor Integra LifeSciences' management team and ensure that shareholders' interests are well served. Integra LifeSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integra LifeSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Burhop, Chief Scientific Officer, Corporate Vice President | |
| Ruth Fleming, Vice Marketing | |
| Eric Schwartz, Corporate Vice President General Counsel, Secretary | |
| Lea Knight, Executive CFO | |
| Mathieu Aussermeier, Investor Finance | |
| Robert Davis, President of Specialty Surgical Solutions and Corporate VP | |
| Maria Platsis, Sr Devel | |
| William Compton, Chief VP | |
| Chantal VeillonBerteloot, Executive Officer | |
| Jeffrey Mosebrook, Principal Accounting Officer, Vice President Corporate Controller | |
| Susan Krause, Corporate Officer | |
| Stuart Hart, Corporate Officer | |
| Mark Jesser, Corporate Officer | |
| Jan Witte, CEO President | |
| Mojdeh Poul, CEO President | |
| Laurene Isip, Vice Relations | |
| Michael McBreen, Executive Surgical | |
| Carrie Anderson, CFO and Principal Financial Officer, Corporate Vice President | |
| Eric JD, Chief VP | |
| Stuart Essig, Chairman of the Board | |
| Jessica Smith, Corporate Officer | |
| Stephen Leonard, Corporate Chain | |
Integra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integra LifeSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to
measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to
predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.